Globus Medical (GMED) EBITDA Margin (2011 - 2026)

Globus Medical (GMED) has reported EBITDA Margin for 16 consecutive years, with 23.1% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA Margin rose 1289.0% year-over-year to 23.1%; the trailing twelve-month figure through Jun 2026 stood at 20.34% (up 962.0% YoY), and the FY2025 full-year result was 16.33%, up 974.0% from the prior year.
• EBITDA Margin grew to 23.1% in Q2 2026 per GMED's latest filing, from 19.79% in the prior quarter.
• Across five years, EBITDA Margin topped out at 25.71% in Q2 2022 and bottomed at 0.11% in Q3 2023.
• Historically, EBITDA Margin has averaged 14.87% across 5 years, with a median of 18.77% in 2022.
• The sharpest annual moves came in 2023 and 2025: EBITDA Margin slumped 2339 bps in 2023, then surged 1490 bps in 2025.
• Over 5 years, EBITDA Margin stood at 19.68% in 2022, then sank by 92 bps to 1.64% in 2023, then jumped by 458 bps to 9.17% in 2024, then soared by 123 bps to 20.49% in 2025, then grew by 13 bps to 23.1% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 23.1%, 19.79%, and 20.49% for Q2 2026, Q1 2026, and Q4 2025 respectively.